Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant

McMaster University

$638,776.00

Revealing the Omnigenic Genetic Architecture of End Stage Renal Disease: Investigating the Cumulative Effect of Rare and Common Genetic Variants

EF 2019-20

Résumé
Purpose: Kidney disease affects 1 in 10 Canadians. 35,000 Canadians currently have kidney failure needing dialysis or a kidney transplant. A cause for kidney failure is unknown in 50% of patients. Kidney disease does not make people unwell until it is advanced. If properly identified, it may be possible to treat people earlier before their kidney disease has progressed. Diet and the environment contribute to kidney disease, but our genes play a large role. Each person has 30,000 genes, and loss of even one gene can cause kidney disease. Over 200 different types of kidney diseases caused by a single gene mutation have been discovered. However, each of these kidney diseases are rare, and together they account for a small proportion of patients with kidney failure. We will look for patients whose kidney disease is due to the total effect of many genes that are working poorly, instead of a single gene that is very abnormal. Procedure: Using the latest genetic testing available, we will test genetic risk factors in 3,700 patients with kidney disease. We will compare these results to more than 500,000 people from the general population. We will then focus on patients who are without a diagnosis to look for new types of kidney disease. Expected Outcome: We will find new combinations of genes that are working poorly that lead patients to develop kidney disease. Relevance to patients: Our research will improve our ability to tell patients what is causing their kidney disease. It will improve our ability to predict who is likely to get worse, even in early stages of kidney disease. We will be able to give better advice to kidney donors about their personal risk of kidney failure. We and others will use our findings to target new treatments for kidney disease.
Programme
Project Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
410054
Name
Lanktree Matthew B
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Genetics
Projecttitle
Revealing the Omnigenic Genetic Architecture of End Stage Renal Disease: Investigating the Cumulative Effect of Rare and Common Genetic Variants
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$638,776
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Chronic Kidney Disease; End-Stage Renal Disease; Exome Sequencing; Genome-Wide Association Studies; Mendelian Randomization; Polygenic Risk Scores; Population Biobanks And Databases; Rare Variant Burden Tests
Abstract
Purpose: Kidney disease affects 1 in 10 Canadians. 35,000 Canadians currently have kidney failure needing dialysis or a kidney transplant. A cause for kidney failure is unknown in 50% of patients. Kidney disease does not make people unwell until it is advanced. If properly identified, it may be possible to treat people earlier before their kidney disease has progressed. Diet and the environment contribute to kidney disease, but our genes play a large role. Each person has 30,000 genes, and loss of even one gene can cause kidney disease. Over 200 different types of kidney diseases caused by a single gene mutation have been discovered. However, each of these kidney diseases are rare, and together they account for a small proportion of patients with kidney failure. We will look for patients whose kidney disease is due to the total effect of many genes that are working poorly, instead of a single gene that is very abnormal. Procedure: Using the latest genetic testing available, we will test genetic risk factors in 3,700 patients with kidney disease. We will compare these results to more than 500,000 people from the general population. We will then focus on patients who are without a diagnosis to look for new types of kidney disease. Expected Outcome: We will find new combinations of genes that are working poorly that lead patients to develop kidney disease. Relevance to patients: Our research will improve our ability to tell patients what is causing their kidney disease. It will improve our ability to predict who is likely to get worse, even in early stages of kidney disease. We will be able to give better advice to kidney donors about their personal risk of kidney failure. We and others will use our findings to target new treatments for kidney disease.
Competitiondate
201909
Approvedterm2
4 yrs 0 mth
Pinamesdelim
Lanktree, Matthew B; Paré, Guillaume
Approvedterm
4 ans 0 mois
Cihrcontribution2
~ $638,776~ $0~